参考文献
1.章友康，刘刚.肾病综合征//谌贻璞.肾内科学.北京：人民卫生出版社，2008：1-12.
2. Zhou FD，Zhao MH，Zou WZ，et al.The changing spectrum of primary glomerular diseases within 15 years：A survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant，2009，24：870-876.
3. Zhou FD，Shen HY，Chen M，et al.The renal histopathological spectrum of patients with nephritic syndrome：an analysis of 1523 patients in a single Chinese centre.Nephrol Dial Transplant，2011，26：3993-3997.
4.苏涛，刘晓玲，张宜苗，等.汞中毒相关性肾小球病的临床病理分析.中华肾脏病杂志，2011，27：333-336.
5. Li SJ，Zhang SH，Chen HP，et al.Mercury-induced membranous nephropathy：clinical and pathological features. Clin J Am Soc Nephrol，2010，5：439-444.
6. Qu Z，Liu G，Li J，et al.Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy.Nephrol Dial Transplant，2012，27：1931-1937.
7. Kuroki A，Shibata T，Honda H，et al.glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis，membranous lupus nephritis，and idiopathic membranous nephropathy.Intern Med，2002，41：936-942.
8. Beck LH Jr，Bonegio RG，Lambeau G，et al.M-type phopholipase A2 receptor as target antigen in idiopathic membranous nephropathy.N Engl J Med，2009，361：11-21.
9. Debiec H，Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.N Engl J Med，2011，364：689-690.
10. Hofstra JM，Beck LH Jr，Beck DM，et al.Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol，2011，6：1286-1291.
11. Wei C，El Hindi S，Li J，et al.Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med，2011，17：952-960.
12. Huang J，Liu G，Zhang YM，et al.Plasma soluble rokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int，2013，84：366-372.
13.周福德，王海燕.难治性肾病综合征.继续医学教育，2006，20：16-20.
14.孙颂山.免疫抑制药//金有豫.药理学.第5版.北京：人民卫生出版社，2001：402-407.
15. Li J，Zhang YM，Qu Z，et al.Low-dose cyclosporine treatment in Chinese nephrotic patients with idiopathic membranous nephropathy：An uncontrolled study with prospective follow-up.Am J Med Sci，2010，339：532-536.
16.环孢素A在肾内科的应用专家协作组.环孢素A治疗肾小球疾病的应用共识.中华肾脏病杂志，2005，21：556-557.
17.吗替麦考酚酯在肾内科应用专家共识组（赵明辉，陆福明整理）.吗替麦考酚酯在肾内科应用专家共识.中华内科杂志，2006，45：965-966.
18. Liu WX，Li DM，Xu GS，et al.Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. Int J Clin Pharmcol Ther，2010，48：509-513.
19. Zhou J，Zhang Y，Liu G，et al.Efficacy and safety of leflunomide in treatment of steroid-dependent and steroidresistant adult onset minimal change disease.Clin Nephrol 2013，80：121-129.
20. Zhang WX，Zhou W，Zhang ZQ，et al.Interstitial lung diseases after leflunomide use in nephropathy：an analysis of reported cases in Chinese literature.Nephrol Dial Transplant，2011，26：1416-1420.
21.谌贻璞，主编.肾脏内科诊疗常规.北京：中国医药科技出版社，2013：1-19.
22. Kidney Disease：Improving Global Outcomes（KDIGO）Glomerulonephritis Work Group.KDIGO Clinical Practice Guidline for Glomerulonephritis.Kidney Int，2012，Suppl 2：139-274.
23. Chen M，Zhou FD，Zhao MH，et al.Normoalbumineaemia is associated with IgA nephropathy in primary glomerulopathy with nephrotic-range proteinuria in Chinese patients.Nephrol Dial Transplant，2011，26：1247-1252.
24. Busch M，Rüster C，Schinköthe C，et al.Rituximab for the second-and thirdline therapy of idiopathic membranous nephropathy：a prosective single center study using a new treatment strategy.Clin Nephrol，2013，80：105-113.
25. Beck LH Jr，Fervenza FC，Beck DM，et al.Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.J Am Soc Nephrol 2011，22：1543-1550.
26. Hingorani SR，Weiss NS，Watkins SL.Predictors of peritonitis in children with nephrotic syndrome.Pediatr Nephrol，2002，17：678-682.
27. Stellato T，Cappelleri A，Farina M，et al.Severe reversible acute renal failure in idiopathic nephrotic syndrome. J Nephrol，2010，23：717-724.
28. Basford AW，Lewis J，Dwyer JP，et al.Membranous nephropathy with crescents.J Am Soc Nephrol，2011，22：1804-1808.
29. Barbour SJ，Greenwald A，Djurdjev Q，et al.Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis.Kidney Int，2012，81：190-195.
30. Kearon C，Akl EA，Comerota AJ，et al. Antithrombotic therapy for VTE disease：Antithrombotic Therapy and Prevention of Thrombosis，9th ed：American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest，2012，141：e419S-494S.
31. Wang C，Zhai Z，Yang Y，et al.Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism：a randomized，multicenter，controlled trial. Chest，2010，137：254-262.
32. Radhakrishnan J，Appel AS，Valeri A，et al.The nephrotic syndrome，lipids，and risk factors for cardiovascular disease.Am J Kidney Dis，1993，22：135-142.